AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Activity: Sulfanilamide belongs to the sulfonamide class of antibiotics, which inhibit the growth and replication of susceptible bacteria by interfering with the synthesis of folic acid, a crucial component for bacterial survival. It is effective against a wide range of gram-positive and gram-negative bacteria.
Historical Use: Sulfanilamide was one of the first synthetic antibiotics developed in the 1930s and played a significant role in the treatment of various bacterial infections before the introduction of newer antibiotics. It was used to treat conditions such as urinary tract infections, respiratory tract infections, wound infections, and sexually transmitted infections.
Topical Formulations: Sulfanilamide is available in various topical formulations, including creams, ointments, powders, and sprays. These formulations are applied directly to the skin or mucous membranes to treat localized bacterial infections, burns, wounds, and other dermatological conditions.
Mechanism of Action: Sulfanilamide works by inhibiting the enzyme dihydropteroate synthase, which is involved in the synthesis of folic acid in bacteria. By blocking this enzyme, sulfanilamide disrupts the production of nucleic acids and proteins essential for bacterial growth and replication, ultimately leading to bacterial death.
Adverse Effects: Sulfanilamide may cause adverse effects in some individuals, including allergic reactions, skin sensitivities, and dermatitis. Hypersensitivity reactions such as rash, itching, swelling, and hives may occur, particularly in individuals with a history of sulfonamide allergy. Severe allergic reactions, although rare, may manifest as anaphylaxis, a life-threatening emergency requiring immediate medical attention.
Drug Interactions: Sulfanilamide may interact with other medications or compounds, including other antibiotics, diuretics, anticoagulants, and certain nonsteroidal anti-inflammatory drugs (NSAIDs). It is essential to consult with a healthcare professional before using sulfanilamide concurrently with other medications to avoid potential interactions or adverse effects.
Regulatory Considerations: The use of sulfanilamide in medical practice is subject to regulations and guidelines established by regulatory authorities to ensure its safe and appropriate use. Healthcare professionals are responsible for prescribing sulfanilamide judiciously, taking into account factors such as the patient's medical history, allergy profile, and susceptibility of the infecting organism.
Consultation with Healthcare Provider: Individuals requiring treatment with sulfanilamide should consult with a qualified healthcare provider for proper diagnosis, treatment recommendations, and monitoring of their condition. Healthcare providers can provide guidance on the appropriate use of sulfanilamide and monitor for any adverse effects or complications associated with its use.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Vibrio | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Vibrio cholerae | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | 0.3 | |
ADHD | 0.6 | 0.6 | |
Allergic Rhinitis (Hay Fever) | 0.9 | 0 | 0 |
Allergies | 1.4 | 1.2 | 0.17 |
Allergy to milk products | 0.6 | 0.9 | -0.5 |
Alzheimer's disease | 2.1 | 1.6 | 0.31 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.3 | 1.67 |
Ankylosing spondylitis | 1.2 | 1.2 | 0 |
Anorexia Nervosa | 0.3 | 1 | -2.33 |
Antiphospholipid syndrome (APS) | 0 | 0 | |
Asthma | 1 | 0.3 | 2.33 |
Atherosclerosis | 1.1 | 0.3 | 2.67 |
Atrial fibrillation | 1 | 0.9 | 0.11 |
Autism | 1.9 | 2.3 | -0.21 |
Autoimmune Disease | 0.6 | 0.6 | |
Barrett esophagus cancer | 0.3 | 0.3 | |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1.1 | 1.1 | |
Bipolar Disorder | 1.2 | 0.3 | 3 |
Brain Trauma | 0.6 | -0.6 | |
Breast Cancer | 0.5 | 0.3 | 0.67 |
Cancer (General) | 0.3 | 0.4 | -0.33 |
Carcinoma | 2 | 0.6 | 2.33 |
Celiac Disease | 0.8 | 0.9 | -0.13 |
Cerebral Palsy | 0.3 | 0.6 | -1 |
Chronic Fatigue Syndrome | 1.3 | 0.9 | 0.44 |
Chronic Kidney Disease | 0.9 | 0.3 | 2 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.6 | -1 |
Chronic Urticaria (Hives) | 0.6 | 0.1 | 5 |
Coagulation / Micro clot triggering bacteria | 0.6 | 0.3 | 1 |
Cognitive Function | 0.6 | 0.6 | |
Colorectal Cancer | 3 | 0.6 | 4 |
Constipation | 1.8 | 1.8 | |
Coronary artery disease | 0.9 | 0.4 | 1.25 |
COVID-19 | 1.8 | 1.3 | 0.38 |
Crohn's Disease | 2.7 | 1.4 | 0.93 |
Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
cystic fibrosis | 0.6 | 0.3 | 1 |
d-lactic acidosis (one form of brain fog) | 0 | 0 | |
deep vein thrombosis | 1.6 | 0.6 | 1.67 |
Denture Wearers Oral Shifts | 0.5 | 0.5 | |
Depression | 2.7 | 1.9 | 0.42 |
Eczema | 0.9 | 0.1 | 8 |
Endometriosis | 0.9 | 0.6 | 0.5 |
Eosinophilic Esophagitis | 0.3 | 0.3 | |
Epilepsy | 1.3 | 0.3 | 3.33 |
erectile dysfunction | 1.2 | 1.2 | |
Fibromyalgia | 0.3 | -0.3 | |
Functional constipation / chronic idiopathic constipation | 1.9 | 0.7 | 1.71 |
gallstone disease (gsd) | 1.4 | 0.3 | 3.67 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.3 | 3 |
Generalized anxiety disorder | 1.2 | 0.3 | 3 |
Gout | 0.6 | 0.3 | 1 |
Graves' disease | 0.6 | 0.6 | 0 |
Gulf War Syndrome | 0.1 | -0.1 | |
Halitosis | 1.1 | 1.1 | |
Hashimoto's thyroiditis | 1 | 0.6 | 0.67 |
Heart Failure | 1.8 | 0.3 | 5 |
hemorrhagic stroke | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.9 | 0.9 | |
High Histamine/low DAO | 0 | 0.3 | 0 |
hypercholesterolemia (High Cholesterol) | 0 | 0 | |
hyperglycemia | 0.6 | 0.3 | 1 |
hypertension (High Blood Pressure | 1.5 | 0.8 | 0.88 |
Hypoxia | 0.9 | 0.9 | |
IgA nephropathy (IgAN) | 0.9 | 0.1 | 8 |
Inflammatory Bowel Disease | 2.2 | 1.7 | 0.29 |
Insomnia | 0.3 | 0.9 | -2 |
Intelligence | 0.3 | 0.3 | |
Intracranial aneurysms | 0.9 | 0.9 | |
Irritable Bowel Syndrome | 1.9 | 1.2 | 0.58 |
ischemic stroke | 0.6 | 0.9 | -0.5 |
Liver Cirrhosis | 1.7 | 0.9 | 0.89 |
Long COVID | 1.8 | 1.6 | 0.13 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0.6 | 0.3 | 1 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 1.1 | 0.3 | 2.67 |
ME/CFS with IBS | 0.3 | -0.3 | |
ME/CFS without IBS | 0 | 0.3 | 0 |
Metabolic Syndrome | 2 | 1.3 | 0.54 |
Mood Disorders | 2.3 | 1.9 | 0.21 |
Multiple Sclerosis | 1.5 | 0.8 | 0.88 |
Multiple system atrophy (MSA) | 0.3 | -0.3 | |
myasthenia gravis | 0.6 | 0.6 | |
neuropathic pain | 0.6 | -0.6 | |
Neuropathy (all types) | 0.6 | -0.6 | |
neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 0.9 | 1 |
NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
Obesity | 1.8 | 2.3 | -0.28 |
obsessive-compulsive disorder | 2 | 0.3 | 5.67 |
Osteoarthritis | 0.9 | 0.6 | 0.5 |
Osteoporosis | 1.2 | 0.3 | 3 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 1.4 | 1.9 | -0.36 |
Polycystic ovary syndrome | 2.3 | 1 | 1.3 |
primary biliary cholangitis | 0.3 | -0.3 | |
Primary sclerosing cholangitis | 0.6 | 0.3 | 1 |
Psoriasis | 0.5 | 0.3 | 0.67 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 0.7 | 2.43 |
Rosacea | 0.3 | 0.3 | |
Schizophrenia | 1.2 | 0.9 | 0.33 |
scoliosis | 0 | 0.3 | 0 |
Sjögren syndrome | 0.6 | 0.3 | 1 |
Sleep Apnea | 0.9 | 0.6 | 0.5 |
Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
Stress / posttraumatic stress disorder | 0.6 | 0.3 | 1 |
Systemic Lupus Erythematosus | 1.3 | 0.6 | 1.17 |
Tic Disorder | 0.6 | 0.6 | |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 1.6 | 1.2 | 0.33 |
Type 2 Diabetes | 2.5 | 1.4 | 0.79 |
Ulcerative colitis | 2.2 | 1 | 1.2 |
Unhealthy Ageing | 1.5 | 1.5 | |
Vitiligo | 1 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]